Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
2 evidence topics · 4 sources
Summary
The multinational adult survey reported a mean of 11.5 attacks over six months, but only 56 of 153 participants using prophylaxis reported a first-line option under the study classification. These findings should not be interpreted as a failure rate for current first-line prophylaxis or as a controlled comparison of drugs. A claims study reported annualized expenditure above $200,000 for on-demand prescriptions, hospitalizations, and emergency department visits even after subcutaneous prophylaxis began. The Cochrane review identified limitations in drawing conclusions about relative efficacy because head-to-head trials were lacking.